Organigram Holdings Inc. (TSE:OGI – Free Report) – Investment analysts at Alliance Global Partners reduced their Q4 2024 earnings per share (EPS) estimates for shares of Organigram in a report released on Monday, December 9th. Alliance Global Partners analyst A. Grey now forecasts that the company will earn ($0.03) per share for the quarter, down from their previous forecast of ($0.02). The consensus estimate for Organigram’s current full-year earnings is $0.16 per share. Alliance Global Partners also issued estimates for Organigram’s Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.03) EPS.
Separately, Canaccord Genuity Group reduced their price objective on shares of Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating on the stock in a research note on Monday.
Organigram Stock Performance
Shares of OGI opened at C$2.17 on Wednesday. The company has a quick ratio of 2.62, a current ratio of 6.95 and a debt-to-equity ratio of 1.13. The company has a 50-day simple moving average of C$2.29 and a 200-day simple moving average of C$2.32. Organigram has a 52-week low of C$1.61 and a 52-week high of C$3.95. The company has a market capitalization of C$235.60 million, a PE ratio of -0.86, a P/E/G ratio of 0.42 and a beta of 1.13.
Insider Activity
In other news, Senior Officer Paolo De Luca sold 12,014 shares of the firm’s stock in a transaction on Thursday, October 24th. The shares were sold at an average price of C$2.52, for a total value of C$30,275.28. Corporate insiders own 31.32% of the company’s stock.
About Organigram
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED’ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Recommended Stories
- Five stocks we like better than Organigram
- What to Know About Investing in Penny Stocks
- UiPath: A Golden Opportunity in AI-Driven Workflow Automation
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Time to Take Bitcoin Profits as $100K Milestone Nears?
- 5 discounted opportunities for dividend growth investors
- 4 Stocks That Crushed Analyst Estimates by More Than Double
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.